Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCHIMEDES: Anti-inflammatory and Anti-thrombotic Strategy in Acute Ischemic Stroke
NCT06396858Phase 4Not yet recruiting
- Sponsor
- Brazilian Clinical Research Institute
- Start
- Jan 2027
- Primary completion
- Jan 2028
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
A Phase 4 trial of rivaroxaban, colchicine in ischemic stroke, sponsored by Brazilian Clinical Research Institute. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
rivaroxabancolchicine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06396858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06396858.